MedTrace Logo

CandeSpartan Study. Candesartan Spanish Response-prediction and Tolerability Study

NCT04138316 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 85

Last updated 2022-12-19

No results posted yet for this study

Summary

Observational, prospective, descriptive, open study on response predictors and tolerability of Candesartan in patients \>18 years with episodic or chronic migraine with prior failure of three or more preventive drugs. Patients will receive Candesartan the same manner and intensity if they were not enrolled in the study. Vital signs, clinical variables and adverse events will be monitored.

Primary endpoint will be to determine demographic and clinical factors associated with a 50% reduction in the frequency of headache days per month between weeks 20 and 24 compared with baseline.

Conditions

Interventions

DRUG

Candesartan

Treatment with Candesartan

Sponsors & Collaborators

  • Hospital Clínico Universitario de Valladolid

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-02
Primary Completion
2022-12-16
Completion
2022-12-16

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04138316 on ClinicalTrials.gov